troglitazone has been researched along with Adrenocorticotropic Hormone, Inappropriate Secretion in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heaney, AP | 1 |
1 review available for troglitazone and Adrenocorticotropic Hormone, Inappropriate Secretion
| Article | Year |
|---|---|
Novel medical approaches for the treatment of Cushing's disease.
Topics: Antineoplastic Agents; Chromans; Humans; Ligands; Pituitary ACTH Hypersecretion; PPAR gamma; Recepto | 2004 |